TCT Featured Clinical Trials to be presented on September 24 in San Francisco

NewsGuard 100/100 Score

WHAT: A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

WHEN: The TCT Featured Clinical Trials will be presented on September 24, 2009 from 2:00 - 6:00 pm.

Session I. Drug-Eluting Stents

  • ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents
    Cheol Whan Lee, MD
  • CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
    Flavio L Ribichini, MD
  • STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
    Josef Veselka, MD, PhD
  • NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Randomized Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
    John A. Spertus, MD
  • CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
    Cheol Whan Lee, MD
  • BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
    Eberhard Grube, MD

Session II. ACS Therapies and Novel Imaging Approaches

  • MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
    Patrick Ohlmann, MD, PhD
  • COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT Francesco Prati, MD
  • NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
    Junbo Ge, MD
  • OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
    Giulio Guagliumi, MD

Session III. End-Stage, Structural Heart and Endovascular Intervention

  • The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
    Josep Rodes-Cabau, MD
  • CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
    David E. Allie, MD
  • ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
    Gary M. Ansel, MD
  • PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
    Dirk H. Walter, MD
  • ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
    Douglas W. Losordo, MD

WHERE: The Moscone Center San Francisco, CA

HOW TO REGISTER: Media may apply for registration by clicking on: http://www.tctconference.com/press/press-registration/press-pre-registration.html

Details on required press credentials can be found at: http://www.tctconference.com/press/press-policies.html

Follow TCT News on Twitter: https://twitter.com/TCTConference.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research explores the health benefits of resistant starch in plant-based diets